MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Kodu・Aktsiate loetelu・Vaxart Inc

Vaxart Inc

Suletud

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Põhinäitajad
By Trading Economics
Sissetulek	63M 55M
Müük	32M 104M
P/E Sektori keskmine	9 66.418
Aktsiakasum	0.24
Kasumimarginaal	52.807
Töötajad	65
EBITDA	63M 58M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-40M 152M
Eelmine avamishind	0
Eelmine sulgemishind	0

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.4007 / 0.4252 Toetus ja vastupanu

Vaxart Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. apr 2026, 17:04 UTC

Suurimad hinnamuutused turgudel

FDA Rejects Replimune's Melanoma Drug for a Second Time

11. apr 2026, 00:00 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Big Yachts, Big Bucks -- Barrons.com

10. apr 2026, 21:55 UTC

Omandamised, ülevõtmised, äriostud

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10. apr 2026, 21:01 UTC

Tulu

Cango Inc.: Files Annual Report on Form 20-F With SEC

10. apr 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

10. apr 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

10. apr 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10. apr 2026, 20:31 UTC

Market Talk

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10. apr 2026, 20:10 UTC

Omandamised, ülevõtmised, äriostud

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10. apr 2026, 19:15 UTC

Market Talk

Global Energy Roundup: Market Talk

10. apr 2026, 19:15 UTC

Market Talk

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10. apr 2026, 19:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10. apr 2026, 19:08 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

10. apr 2026, 18:38 UTC

Market Talk

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

10. apr 2026, 18:25 UTC

Market Talk

Uudisväärsed sündmused

Precious Metals Finish With Weekly Gains -- Market Talk

10. apr 2026, 18:05 UTC

Market Talk

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

10. apr 2026, 17:31 UTC

Market Talk

Uudisväärsed sündmused

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

10. apr 2026, 17:26 UTC

Tulu

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

10. apr 2026, 17:10 UTC

Market Talk

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

10. apr 2026, 17:00 UTC

Uudisväärsed sündmused

Construction Business Taking a Hit From Iran Conflict -- WSJ

10. apr 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

10. apr 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

10. apr 2026, 16:12 UTC

Tulu

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

10. apr 2026, 16:11 UTC

Tulu

Partners Group: Traditional Programs Contributed $3.3B

10. apr 2026, 16:10 UTC

Tulu

Partners Group: $5B of New Commitments Came From Bespoke Solutions

10. apr 2026, 16:10 UTC

Tulu

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

10. apr 2026, 16:10 UTC

Tulu

Partners Group 1Q New Client Demand $8.3B

10. apr 2026, 16:09 UTC

Tulu

Partners Group Continued to See Positive Fundraising Momentum in 1Q

10. apr 2026, 15:54 UTC

Omandamised, ülevõtmised, äriostud

Plenitude Completes Acquisition of Acea Energia

10. apr 2026, 15:38 UTC

Market Talk

Global Energy Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Vaxart Inc Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Vaxart Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.4007 / 0.4252Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.